Enterprise Value
-1.571M
Cash
12.45M
Avg Qtr Burn
-7.003M
Short % of Float
0.96%
Insider Ownership
0.05%
Institutional Own.
29.16%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CYAD-231 (NKG2DL) Details Solid tumor/s, Cancer | Failed Discontinued | |
CYAD-221 (CD19) Details B-cell malignancies, Diffuse large B cell lymphoma, Cancer | Failed Discontinued | |
CYAD-02 (NKG2DL) Details Myelodysplastic syndrome, Blood cancer, Acute myeloid leukemia, Cancer | Failed Discontinued | |
CYAD-01 Details Myelodysplastic syndrome, Blood cancer, Cancer, Acute myeloid leukemia, Multiple myeloma | Failed Discontinued | |
CYAD-101 Details Metastatic colorectal cancer, Cancer | Failed Discontinued | |
CYAD-211 (BCMA) Details Multiple myeloma, Cancer | Failed Discontinued | |
CYAD-103 (NKG2DL) Details Solid tumor/s, Cancer | Failed Discontinued |